EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische Übersicht

Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis

Omotayo Segun-Omosehin, Natalie E Bourdakos, Kosta G Tzanis, Marie Michele Macaron, Fares Jamal, Lisa Marks, Abdullah Hamad, Talha A Malik

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-09948-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Omotayo Segun-Omosehin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Inflammatory Bowel Diseases, Pregnancy Complications. Die Arbeit nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Biologic therapies, including tumor necrosis factor (TNF) blockers, vedolizumab (VDZ), and ustekinumab (UST), are generally considered safe during pregnancy in patients with inflammatory bowel disease (IBD), though comparative data remain limited. This meta-analysis examines their safety and effectiveness. METHODS: A systematic search of MEDLINE, EMBASE, CINAHL, Cochrane, and Web of Science was conducted through July 2025. Eligible studies reported maternal or neonatal outcomes in pregnant IBD patients treated with biologics. Studies were pooled using a random-effects model to calculate risk ratios (RRs) with 95% confidence intervals. Heterogeneity was assessed using I2. Primary outcomes were preterm birth and disease activity; secondary outcomes included pregnancy and neonatal outcomes. RESULTS: Nine observational studies (n = 6,054) were included. Compared to TNF blockers, VDZ was associated with a higher risk of preterm delivery (RR = 1.35, 95% CI 1.04-1.75, I2 = 0%) and active disease (RR = 1.55, 95% CI 1.01-2.40, I2 = 50%). UST was associated with a higher risk of active disease (RR = 1.30, 95% CI 1.06-1.60, I2 = 0%) and congenital anomalies (RR = 2.08, 95% CI 1.30-3.32, I2 = 0%) compared to TNF blockers. Compared to UST, VDZ was linked to increased risks of preterm birth (RR = 2.60, 95% CI 1.03-6.57, I2 = 0%) and low birth weight (RR = 2.38, 95% CI 1.01-5.60, I2 = 0%). No significant differences were observed for live births, abortions, hospitalizations, or neonatal infections. CONCLUSION: TNF blockers showed a favorable safety and effectiveness profile, VDZ and UST performed broadly similar, and all three biological classes appeared compatible with safe use in pregnancy to maintain effective disease control. Observed differences reflect that VDZ and UST cohorts likely had longer disease duration, prior biologic exposure, and more active disease. The results of this meta-analysis support the continuation of biologic therapy for disease control in pregnant patients with IBD. Treatment decisions should be individualized and tailored to each patient's clinical context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsInflammatory Bowel DiseasesPregnancy ComplicationsTumor Necrosis Factor InhibitorsUstekinumabFemaleHumansPregnancyPregnancy OutcomePremature BirthTreatment OutcomeTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

BiologicsInflammatory bowel diseaseMeta-analysisPregnancySystematic review

Substanzen

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor InhibitorsTumor Necrosis Factor-alphaUstekinumabvedolizumab

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
  • Department of General Surgery, Guthrie Robert Packer Hospital, Sayre, PA, 18840, USA.
  • University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.
  • George's University of London, London, SW17 0RE, UK.
  • Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
  • Library Services, Mayo Clinic, Phoenix, AZ, 85054, USA.

Zitieren

APA

Segun-Omosehin, O., Bourdakos, N. E., Tzanis, K. G., Macaron, M. M., Jamal, F., Marks, L., Hamad, A., & Malik, T. A. (2026). Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09948-w

Vancouver

Segun-Omosehin O, Bourdakos NE, Tzanis KG, Macaron MM, Jamal F, Marks L, et al. Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09948-w

BibTeX
@article{SegunOmosehin2026,
  author = {Segun-Omosehin, Omotayo and Bourdakos, Natalie E and Tzanis, Kosta G and Macaron, Marie Michele and Jamal, Fares and Marks, Lisa and Hamad, Abdullah and Malik, Talha A},
  title = {Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-09948-w}
}
Kostenlos starten →